NCT06049212: Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) |
|
|
| Recruiting | 1 | 36 | Japan | Sacituzumab tirumotecan, SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin | Merck Sharp & Dohme LLC | Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) | 06/25 | 06/25 | | |
